摘要
目的:分析茚达特罗格隆溴铵吸入粉雾剂联合糜蛋白酶治疗COPD频繁急性加重表型的临床效果。方法:选取于2022年5月—2023年5月在粤北人民医院收治的128例COPD频繁急性加重表型患者作为研究对象,根据随机数字表法分为对照组(n=64)和试验组(n=64)。对照组给予茚达特罗格隆溴铵吸入粉雾剂治疗,试验组在对照组的基础上联合糜蛋白酶治疗,两组均持续治疗6个月。对比两组肺功能(FEV_(1)、FVC、FEV_(1)/FVC)、症状严重程度[6 min步行距离(6MWD)、改良版英国医学研究委员会呼吸困难问卷(mMRC)评分]、炎症因子(IL-8、IL-17)及不良反应。结果:治疗6个月后,两组的FEV_(1)、FVC、FEV_(1)/FVC高于治疗前,6MWD长于治疗前,mMRC评分、IL-8、IL-17低于治疗前(P<0.05);治疗6个月后,试验组的FEV_(1)、FVC、FEV_(1)/FVC高于对照组,6MWD长于对照组,mMRC评分、IL-8、IL-17低于对照组(P<0.05)。试验组的不良反应发生率(14.06%)稍高于对照组(9.38%),但两组差异无统计学意义(P>0.05)。结论:COPD频繁急性加重表型患者采取茚达特罗格隆溴铵吸入粉雾剂联合糜蛋白酶治疗可以明显改善患者相关症状,促进肺功能恢复,降低炎症因子水平,且不增加不良反应。
Objective:To analyze the clinical effect of Indacaterol Maleate and Glycopyrronium Bromide Powder for Inhalation combined with Chymotrypsin in the treatment of frequent acute exacerbation phenotype of COPD.Method:A total of 128 patients with the frequent acute exacerbation phenotype of COPD admitted to Yuebei People's Hospital from May 2022 to May 2023 were selected as the research subjects.They were divided into the control group(n=64)and the experimental group(n=64)according to the random number table method.The control group was treated with Indacaterol Maleate and Glycopyrronium Bromide Powder for Inhalation,and the experimental group was treated with Chymotrypsin on the basis of the control group.Both groups were continuously treated for 6 months.The lung function(FEV_(1),FVC,FEV_(1)/FVC),symptom severity[6-minute walk distance(6MWD),modified medical research council dyspnea questionnaire(mMRC)score],inflammatory factors(IL-8,IL-17)and adverse reactions were compared between the two groups.Result:After 6 months of treatment,the FEV_(1),FVC,FEV_(1)/FVC in both groups were higher than those before treatment,6MWD were longer than those before treatment,while the mMRC score,IL-8,and IL-17 were lower than those before treatment(P<0.05).After 6 months of treatment,the FEV_(1),FVC,FEV_(1)/FVC in the experimental group were higher than those in the control group,6MWD was longer than that in the control group,while the mMRC score,IL-8 and IL-17 were lower than those in the control group(P<0.05).The incidence of adverse reactions in the experimental group(14.06%)was slightly higher than that in the control group(9.38%),but there was no statistically significant difference between the two groups(P>0.05).Conclusion:For patients with the frequent acute exacerbation phenotype of COPD,the treatment with Indacaterol Maleate and Glycopyrronium Bromide Powder for Inhalation combined with Chymotrypsin can significantly improve the relevant symptoms of patients,promote the recovery of lung function,reduce the levels of inflammatory factors,and does not increase adverse reactions.
作者
彭峰
程江涛
侯红梅
姜芳芳
PENG Feng;CHENG Jiangtao;HOU Hongmei;JIANG Fangfang(Department of Respiratory and Critical Care Medicine,Yuebei People's Hospital,Shaoguan 512026,China;不详)
出处
《中国医学创新》
2025年第35期125-128,共4页
Medical Innovation of China
基金
韶关市卫生健康科研项目(Y22068)
韶关市社会发展科技协同创新体系建设项目(220606084532034)。
关键词
茚达特罗格隆溴铵吸入粉雾剂
糜蛋白酶
慢性阻塞性肺疾病
频繁急性加重表型
Indacaterol Maleate and Glycopyrronium Bromide Powder for Inhalation
Chymotrypsin Chronic obstructive pulmonary disease
Frequent acute exacerbation phenotype
